These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 15730807)

  • 1. [Biological characteristics of HIV-1 isolates circulating in China are linked to its env V3 loop sequence variability].
    Hei FX; Hong KX; Song YH; Tang HL; Peng H; Xu JQ; Xing H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(23):1968-72. PubMed ID: 15730807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage.
    Xiao L; Owen SM; Goldman I; Lal AA; deJong JJ; Goudsmit J; Lal RB
    Virology; 1998 Jan; 240(1):83-92. PubMed ID: 9448692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of neutralization sensitivity of HIV-1 primary isolates with biological properties of isolates from HIV-1 infected Chinese individuals.
    Hei FX; Tang HL; Hong KX; Chen JP; Peng H; Yuan L; Xu JQ; Shao YM
    Biomed Environ Sci; 2005 Apr; 18(2):128-36. PubMed ID: 16001833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.
    Jansson M; Backström E; Björndal A; Holmberg V; Rossi P; Fenyö EM; Popovic M; Albert J; Wigzell H
    J Hum Virol; 1999; 2(6):325-38. PubMed ID: 10774549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates.
    Coetzer M; Cilliers T; Ping LH; Swanstrom R; Morris L
    Virology; 2006 Dec 5-20; 356(1-2):95-105. PubMed ID: 16942785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.
    Raymond S; Delobel P; Mavigner M; Cazabat M; Souyris C; Sandres-Sauné K; Cuzin L; Marchou B; Massip P; Izopet J
    AIDS; 2008 Sep; 22(14):F11-6. PubMed ID: 18753930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and biological characterization of HIV-1 BG intersubtype recombinants and other genetic forms circulating in Galicia, Spain.
    Pérez-Alvarez L; Muñoz M; Delgado E; Miralles C; Ocampo A; García V; Thomson M; Contreras G; Nájera R;
    J Med Virol; 2006 Dec; 78(12):1520-8. PubMed ID: 17063519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop.
    Sato H; Kato K; Takebe Y
    Virology; 1999 May; 257(2):491-501. PubMed ID: 10329559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1.
    Tscherning C; Alaeus A; Fredriksson R; Björndal A; Deng H; Littman DR; Fenyö EM; Albert J
    Virology; 1998 Feb; 241(2):181-8. PubMed ID: 9499793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between V3 genotype, biologic phenotype, tropism, and coreceptor use for primary isolates of human immunodeficiency virus type 1.
    McDonald RA; Chang G; Michael NL
    J Hum Virol; 2001; 4(4):179-87. PubMed ID: 11694845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
    Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
    Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic and phenotypic analysis of the env gene from South African HIV-1 subtype B and C isolates.
    Treurnicht FK; Smith TL; Engelbrecht S; Claassen M; Robson BA; Zeier M; van Rensburg EJ
    J Med Virol; 2002 Oct; 68(2):141-6. PubMed ID: 12210400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
    Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
    Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on the evolutionary pressure on the env gene of the human immunodeficiency virus type 1 CRF01-AE strains circulating in China].
    Liang H; Xing H; Wei M; Chen Z; Guan Q; Huang HL; Quan Y; Chen JP; Hong KX; Shi LY; Shao YM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):966-70. PubMed ID: 14687493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development.
    Zhang C; Xu S; Wei J; Guo H
    Int J Infect Dis; 2009 Sep; 13(5):e212-6. PubMed ID: 19217335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
    Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
    J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.